Immunocore Holdings Plc Sponsored ADR IMCR 深 沪
等待开盘 08-12 09:30:00 美东时间
31.89
-0.080
-0.25%
华盛通- 最 高32.245
- 今 开32.18
- 成交量 27.62万股
- 最 低 31.02
- 昨 收 31.97
- 总市值 16.02亿
- 52周最高 39.3295
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 23.15
- 委 比 -13.61%
- 总股本 5023.36万
- 历史最高 76.98
- 量 比 0.72
- 振 幅 3.83%
- 历史最低 18.43
- 每 手 1
- 风险率 13.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Immunocore reports second quarter financial results and provides a business update
Immunocore Holdings plc reported Q2 2025 net revenues of $98.0 million for KIMMTRAK, a 30% year-over-year increase. The company is advancing multiple clinical trials, including TEBE-AM (expected to complete enrollment in 1H 2026) and PRISM-MEL-301 (dose selection expected in 2H 2025). They also presented IMC-I109V HBV data at the 2025 AASLD Liver Meeting. Cash, cash equivalents, and marketable securities totaled $883 million as of June 30, 2025. ...
08-07 11:00
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
Immunocore Holdings plc (Nasdaq: IMCR), a biotech company specializing in immunomodulating medicines for cancer, infectious, and autoimmune diseases, announced it will release its Q2 financial results before US markets open on August 7, 2025. A live teleconference and webcast to discuss the results will follow at 8:00 a.m. EDT (1:00 p.m. BST). Immunocore’s ImmTAX platform focuses on TCR bispecific immunotherapies, with KIMMTRAK approved for treat...
07-31 06:00
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Immutep Limited announces positive initial data from its Phase I study of IMP761, a novel LAG-3 agonist antibody for autoimmune diseases. Results show significant T cell suppression and a favorable safety profile at the 0.9 mg/kg dose level. IMP761 has the potential to silence dysregulated T cells, offering a targeted approach with fewer side effects. The study will continue with higher single ascending doses of 2.5, 7, and 14 mg/kg, with additio...
06-23 12:00
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
During the last three months, 9 analysts shared their evaluations of Immunocore...
06-03 05:00
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
Immunocore's management will participate in the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 11:05 a.m. EDT. The event will be available via webcast on Immunocore's investor webpage and replayed for limited time. Immunocore is a biotech company developing innovative TCR bispecific immunotherapies for cancer, autoimmune diseases, and infectious diseases. Their lead oncology product, KIMMTRAK, has been approved in multiple region...
06-02 11:00
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Results from the Phase 1b trial of IMA203 PRAME cell therapy in 33 heavily pretreated metastatic melanoma patients show favorable tolerability and durable clinical activity, with a confirmed ORR of 56%, mDOR of 12.1 months, mPFS of 6.1 months, and mOS of 15.9 months. Subgroup analyses demonstrate strong responses in both cutaneous (cORR 50%) and uveal melanoma (cORR 67%). These findings support the ongoing SUPRAME Phase 3 trial and highlight Imma...
05-31 12:00
Immuron Letter to Shareholders: Projects Update
Immuron Limited reported record sales of $7 million for FY2025, up from $4.9 million last year. Key updates include: Travelan® clinical study results expected in October 2025; IMM-529 IND submission to FDA in August 2025 forClostridioides difficile infection; ProIBS® launch in Australia planned for January 2026; and IMM-986 pre-clinical results anticipated in August 2025 for Vancomycin-resistant enterococci. Sales momentum continued through Easte...
05-30 10:00
Oppenheimer Maintains Outperform on Immunocore Holdings, Raises Price Target to $86
Oppenheimer analyst Jeff Jones maintains Immunocore Holdings (NASDAQ:IMCR) with a Outperform and raises the price target from $85 to $86.
05-08 22:28
